Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington’s disease
Authors:
- 9 July 2024
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 24 (9) , 849-863
Abstract
Tardive dyskinesia (TD) and Huntington's disease (HD)-associated chorea are persistent and disabling hyperkinetic disorders that can be treated with vesicular monoamine transporter type 2 (VMAT2) inhibitors, including the recently approved once-daily (QD) formulation of deutetrabenazine (DTBZ ER). While its efficacy and safety profile have not been directly investigated, currently available data confirms bioequivalence and similar bioavailability to the twice-daily formulation (DTBZ BID). The authors briefly review the pivotal trials establishing efficacy of DTBZ for TD and HD-associated chorea, the pharmacokinetic data for bioequivalence between QD and BID dosing of DTBZ, as well as dose proportionality evidence, titration recommendations, and safety profile for DTBZ ER. Long-term data show that DTBZ is efficacious and well tolerated for the treatment of TD and HD-associated chorea. DTBZ ER likely demonstrates therapeutic equivalence with no new safety signals. Due to the lack of comparative clinical trial data, no evidence-based recommendation about choice of VMAT2 inhibitor or switching between VMAT2 inhibitors can be made about best practice. Ultimately, QD dosing may offer the chance of improved medication adherence, an important consideration in patients with complex treatment regimens and/or patients with cognitive decline.Keywords
This publication has 153 references indexed in Scilit:
- A Bioequivalence Comparison Between the Once‐Daily Extended‐Release Tablet and the Twice‐Daily Tablet Formulations of Deutetrabenazine at Steady StateClinical Pharmacology in Drug Development, 2024
- Pharmacokinetic and Pharmacologic Characterization of the Dihydrotetrabenazine Isomers of Deutetrabenazine and ValbenazineClinical Pharmacology in Drug Development, 2022
- Evaluation of Deutetrabenazine's Potential to Delay Cardiac Repolarization Using Concentration‐QTc AnalysisClinical Pharmacology in Drug Development, 2022
- Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette SyndromeJAMA Network Open, 2021
- Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette SyndromeJAMA Network Open, 2021
- Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food EffectClinical Pharmacology in Drug Development, 2020
- Benzodiazepines for antipsychotic-induced tardive dyskinesiaCochrane Database of Systematic Reviews, 2018
- Anticholinergic medication for antipsychotic-induced tardive dyskinesiaCochrane Database of Systematic Reviews, 2018
- Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?Movement Disorders Clinical Practice, 2017
- Effect of Deutetrabenazine on Chorea Among Patients With Huntington DiseaseJAMA, 2016